On April 2, 2026 — exactly one year after the original "Liberation Day" tariffs that were later struck down by the Supreme Court — President Donald Trump signed an executive order imposing 100% tariffs on patented pharmaceutical products and their active ingredients imported into the United States. The move, framed under Section 232 of the Trade Expansion Act as a national security measure, represents the most aggressive trade intervention in the global pharmaceutical sector in modern history. For procurement professionals operating in health, infrastructure, and supply chain sectors, the implications are both immediate and far-reaching.
The Tariff Structure: A Tiered System with Exemptions
The executive order establishes a multi-tiered tariff regime that varies significantly depending on a company's relationship with the U.S. government and its country of origin.
At the top of the scale, companies that have not entered into any agreements with the administration face the full 100% tariff on patented pharmaceutical products and their ingredients. This rate applies to both finished dosage forms and active pharmaceutical ingredients (APIs).
However, the tariff drops significantly for companies willing to negotiate:
- 0% tariff through January 20, 2029, for companies that sign both a Most Favored Nation (MFN) pricing agreement with the Department of Health and Human Services and an onshoring agreement with the Department of Commerce
- 20% tariff for companies that commit to building manufacturing facilities in the United States but have not completed MFN pricing deals
- 15% tariff for products originating in the European Union, Japan, South Korea, Switzerland, and Liechtenstein — matching previously agreed trade deal rates
- 10% tariff for products from the United Kingdom, with provisions for further reductions under future trade agreements
Critically, generic pharmaceuticals, biosimilars, orphan drugs, animal health medications, and certain specialty products meeting urgent public health needs are currently exempt. The administration has committed to reassessing the generic drug exemption within one year.
Large pharmaceutical companies have 120 days to negotiate and comply, while smaller companies that rely on contract manufacturers receive 180 days.
$400 Billion in Manufacturing Investment Commitments
Perhaps the most consequential procurement story embedded in this executive order is the wave of domestic manufacturing investment it has triggered. The White House announced that approximately $400 billion in new investment commitments have already materialized from pharmaceutical manufacturers seeking to qualify for the 0% tariff pathway.
Of the 17 major pharmaceutical companies targeted by the administration, 15 have already signed MFN pricing and manufacturing agreements. The nine most recent signatories include Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche), Gilead, GSK, Merck, Novartis, and Sanofi. Earlier agreements were reached with Pfizer, AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, and Johnson & Johnson.
These commitments translate directly into procurement activity: new pharmaceutical manufacturing plants, API production facilities, quality control laboratories, packaging operations, and supply chain infrastructure — all of which require engineering, construction, equipment supply, and professional consulting services.
The construction of a modern pharmaceutical manufacturing facility typically involves contracts worth $500 million to $2 billion each, spanning civil works, cleanroom installation, HVAC systems, water purification, process equipment, and validation services. With 15 major companies committing to new or expanded U.S. facilities, the combined procurement pipeline could exceed $50 billion in construction and equipment tenders alone over the next three to five years.
Impact on Global Health Procurement
MDB-Funded Health Programs
The tariff regime creates ripple effects well beyond U.S. borders. International development organizations — including the World Bank, the Asian Development Bank, and the African Development Bank — collectively finance billions of dollars in health programs across developing countries each year. These programs rely on complex pharmaceutical supply chains that are now subject to potential disruption.
While the generic drug exemption shields much of the developing world's essential medicine supply in the short term, the one-year reassessment clause injects significant uncertainty. Countries in Sub-Saharan Africa and South Asia that depend on generic HIV, tuberculosis, and malaria treatments — largely sourced from India and Bangladesh — face the prospect of future cost increases if the exemption is narrowed or removed.
The broader concern is indirect price inflation. When major pharmaceutical companies restructure their global supply chains to prioritize U.S. manufacturing, the remaining international capacity faces potential constraints. API suppliers in India and China, which serve both the U.S. market and global health programs, may see price increases as demand shifts and production lines are reallocated.
WHO and UNICEF Procurement
The World Health Organization and UNICEF, which together procure hundreds of millions of dollars in essential medicines annually for developing countries, are closely monitoring the situation. While their procurement largely involves generic and off-patent medicines currently exempted from the tariffs, any future extension to generics or active ingredients could fundamentally alter the economics of global health procurement.
Stephen Ubl, CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), warned that "taxes on cutting-edge medicines will increase costs and could jeopardize billions in US investments," noting that pharmaceutical imports overwhelmingly originate from allied nations.
Procurement Implications by Sector
Pharmaceutical Construction and Engineering
The most immediate procurement opportunity lies in pharmaceutical facility construction. Companies committed to U.S. onshoring will need:
- Architectural and engineering design services for GMP-compliant facilities
- Civil works contractors for site preparation, foundation, and structural construction
- Cleanroom and HVAC system suppliers
- Process equipment manufacturers and integrators
- Validation and commissioning consultants
- Environmental compliance and permitting specialists
Medical Supplies and Equipment
The same-day announcement of restructured steel, aluminum, and copper tariffs at 50% for pure metal products and 25% for derivative products (effective April 6, 2026) compounds the impact on medical equipment procurement. Surgical instruments, imaging equipment, hospital furniture, and laboratory apparatus all contain significant metal components. Health-sector procurement tenders globally may see cost escalations of 5-15% on equipment categories with high metal content.
API Supply Chain
The active pharmaceutical ingredient sector faces the most complex procurement adjustment. India produces approximately 60% of the world's generic medicines and relies heavily on China for raw chemical intermediates. As U.S. pharmaceutical companies onshore API production, the global supply-demand balance for key chemical intermediates will shift, potentially affecting prices for procurement agencies worldwide.
Countries and Regions Affected
United States
The primary market for these tariffs. U.S.-based health procurement agencies, hospital networks, and government programs (Medicare, Medicaid, Veterans Affairs) face the most direct impact. Companies not participating in MFN deals will pass tariff costs to end purchasers.
European Union
European pharmaceutical powerhouses — including companies headquartered in Switzerland, Germany, France, and Denmark — face a 15% tariff on products not covered by MFN agreements. The EU pharmaceutical industry exported approximately EUR 300 billion in 2025, with the United States as its largest single market. Companies like Novartis, Roche, Sanofi, and Novo Nordisk have already signed agreements to mitigate the impact.
India and Bangladesh
The generic drug exemption is a lifeline for India's $50 billion pharmaceutical export industry and Bangladesh's growing generics sector. However, the one-year review period creates uncertainty for procurement planning. India and Bangladesh remain critical supply sources for global health tenders.
Japan and South Korea
Both countries face the 15% tariff rate under their existing trade arrangements. Major pharmaceutical manufacturers in these countries — including Takeda, Astellas, Daiichi Sankyo (Japan), and Samsung Biologics, Celltrion (South Korea) — must navigate the new tariff landscape while maintaining competitiveness in U.S. and global markets.
Sub-Saharan Africa
African countries that rely almost entirely on imported pharmaceuticals are exposed to second-order effects: supply chain disruptions, potential price increases as manufacturers prioritize U.S. market demand, and the risk of future generic tariff extensions. AfDB-funded health programs across the continent should factor these risks into procurement planning.
What This Means for Contractors
For procurement professionals and companies operating in international health and medical tenders, this tariff action creates several actionable opportunities:
- Pharmaceutical construction firms should monitor facility investment announcements from the 15 companies that have signed MFN deals. Each onshoring commitment represents billions in construction and engineering contracts.
- Medical equipment suppliers should prepare for cost recalculations across tenders incorporating steel and aluminum components, given the simultaneous metals tariff restructuring.
- Consulting firms specializing in pharmaceutical regulatory affairs, supply chain optimization, and trade compliance will see strong demand as companies restructure their global manufacturing footprints.
- API manufacturers in non-tariff jurisdictions may find new opportunities as companies diversify sourcing away from tariff-exposed supply chains.
- Health sector consultants working with MDB-funded programs should advise clients on supply chain risk mitigation strategies, including dual-sourcing of critical medicines and API pre-qualification of alternative suppliers.
Monitor the latest opportunities across all sectors on BidsFactory's tender listings.
Looking Ahead
The next critical milestones are the 120-day and 180-day compliance deadlines (August and October 2026), when companies without agreements will face the full 100% tariff. The administration's one-year review of the generic drug exemption — expected around April 2027 — will be a defining moment for global health procurement.
With $400 billion in committed pharmaceutical manufacturing investments and a fundamental restructuring of global pharma supply chains underway, procurement professionals across infrastructure, health, and supply chain sectors should position themselves now to capture the emerging opportunities.
Browse the latest health and medical tenders, consulting opportunities, and construction works on BidsFactory to stay ahead of this market shift.
